Drugs / gp91 Grans
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05189925 | Jul 2022 → Jul 2027 expected | chronic granulomatous disease, infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp91-Grans | “IV infusion of gp91-Grans at dose K: 1e6 cells/kg” NCT05189925 ↗ |
| Known as | CGD-Grans | “The study agent is one administration of autologous CGD mRNA transfected granulocyte-enriched cells, referred to as CGD-Grans.” NCT05189925 ↗ |
| Action | Restore | “restore protein expression and phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase function” NCT05189925 ↗ |
| Modality | Messenger RNA (mRNA) | “The study agent is one administration of autologous CGD mRNA transfected granulocyte-enriched cells” NCT05189925 ↗ |
| Route | Intravenous | “administered as an intravenous (IV) infusion” NCT05189925 ↗ |